瑞舒伐他汀联合琥珀酸美托洛尔缓释片对心房颤动患者载脂蛋白、非HDL-C/HDL-C比值及肝功能的影响  

Effect of treatment with Rosuvastatin combined with metoprolol succinate extended-release tablets on apolipoproteins,non-HDL-C/HDL-C ratio,and liver function in patients with atrial fibrillation

作　　者：朱伟业 李刚 汤华萍[1] ZHU Wei-ye;LI Gang;TANG Hua-ping(Department of Geriatrics,Ma'anshan People s Hospital,Ma anshan 243000,Anhui,China)

机构地区：[1]马鞍山市人民医院老年医学科,安徽马鞍山243000

出　　处：《川北医学院学报》2025年第3期298-301,309,共5页Journal of North Sichuan Medical College

基　　金：安徽省自然科学基金项目(2008085QH441)。

摘　　要：目的:探讨瑞舒伐他汀联合琥珀酸美托洛尔缓释片对心房颤动患者载脂蛋白、非高密度脂蛋白胆固醇(HDL-C)/HDL-C比值及肝功能的影响。方法:选取102例心房颤动患者作为研究对象,依据治疗方案不同分为对照组及联合组,每组各51例。对照组采用琥珀酸美托洛尔缓释片治疗;联合组在对照组基础上联合瑞舒伐他汀治疗,两组均连续治疗6个月。记录并比较两组患者血脂、炎症、肝功能、房颤发作情况、心功能、治疗效果及不良反应发生情况。结果:治疗后,联合组载脂蛋白A(ApoA)及非HDL-C/HDL-C比值均低于对照组,载脂蛋白B(ApoB)水平高于对照组(P<0.05);联合组超敏C反应蛋白(hs-CRP)及白细胞介素6(IL-6)水平均低于对照组(P<0.05),两组患者丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)水平无统计学差异(P>0.05)。治疗后,联合组房颤持续时间及房颤发作次数水平均低于对照组(P<0.05);联合组左心房容积(LAV)水平低于对照组,左心房射血分数(LAEF)水平高于对照组(P<0.05);联合组治疗有效率高于对照组(P<0.05)。两组患者不良反应总发生率无统计学差异(P>0.05)。结论:采用瑞舒伐他汀联合琥珀酸美托洛尔缓释片治疗,利于降低心房颤动患者血脂及炎症水平,有助于改善患者心功能,治疗效果显著,具有良好的临床效果。Objective:To investigate the effects of rosuvastatin combined with metoprolol succinate on apolipoproteins,non-high-density lipoprotein cholesterol(non-HDL-C)/high-density lipoprotein cholesterol(HDL-C) ratio,and liver function in patients with atrial fibrillation.Methods:102 patients with atrial fibrillation were divided into a control group and a combination group based on different treatment regimens,with 51 cases in each group.The control group was treated with metoprolol succinate,while the combination group received rosuvastatin in addition to the treatment given to the control group.Both groups were treated continuously for 6 months.Blood lipids,inflammation markers,liver function,atrial fibrillation episodes,cardiac function,treatment efficacy,and adverse reactions were recorded and compared between the two groups.Results:After treatment,the levels of apolipoprotein A(ApoA) and non-HDL-C/HDL-C in the combination group were lower than those in the control group,while the level of apolipoprotein B(ApoB) was higher in the combination group(P<0.05).The levels of high-sensitivity C-reactive protein(hs-CRP) and interleukin-6(IL-6) in the combination group were also lower than those in the control group(P<0.05).There was no significant difference in alanine aminotransferase(ALT) and aspartate aminotransferase(AST) levels between the two groups(P>0.05).After treatment,the duration and frequency of atrial fibrillation episodes in the combination group were lower than those in the control group(P<0.05),the left atrial volume(LAV) in the combination group was lower,and the left atrial ejection fraction(LAEF) was higher than in the control group(P<0.05),the effective treatment rate in the combination group was higher than in the control group(P<0.05).The incidence of adverse reactions was not significantly different between the two groups(P>0.05).Conclusion:The treatment with rosuvastatin combined with metoprolol succinate is beneficial in reducing blood lipids and inflammation levels in patients with atrial fibrilla

关 键 词：瑞舒伐他汀 琥珀酸美托洛尔缓释片 心房颤动 血脂 肝功能 

分 类 号：R541.75[医药卫生—心血管疾病]